Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST
Company Participants
Robert DeVita
David Hung – Founder, President, CEO & Chairman
Colleen Sjogren – Chief Commercial Officer
Philippe Sauvage – CFO & Principal Financial Officer
Conference Call Participants
Kaveri Pohlman – Clear Street LLC
Farzin Haque – Jefferies LLC, Research Division
Soumit Roy – JonesTrading Institutional Services, LLC, Research Division
Leonid Timashev – RBC Capital Markets, Research Division
Yaron Werber – TD Cowen, Research Division
David Nierengarten – Wedbush Securities Inc., Research Division
Silvan Tuerkcan – Citizens JMP Securities, LLC, Research Division
Presentation
Operator
Hello, and welcome to Nuvation Bio’s Third Quarter 2025 Financial Results and Corporate Update Call. Today’s call is being recorded, and a replay will be available. [Operator Instructions]
Now I’d like to turn the call over to JR DeVita, Executive Director of Corporate Development and Investor Relations at Nuvation Bio. Please go ahead.
Robert DeVita
Thank you, and good afternoon, everyone. Welcome to the Nuvation Bio Third Quarter 2025 Earnings Conference Call. Earlier today, we released financial results for the quarter ending September 30, 2025, and provided a business update. The press release is available on the Investors section of our website at nuvationbio.com, and a recording of this conference call will also be available on our website following its completion.
I’d like to remind you that today’s call includes forward-looking statements, including statements about the therapeutic and commercial potential of IBTROZI and safusidenib, the components of our anticipated product revenue, expected milestone payments and our cash runway. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the U.S. Securities
